TGL clinical User Guide

Similar documents
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide

The Next Generation of Hereditary Cancer Testing

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

Learn your genetic risk for the most common hereditary cancers.

Genetic Risk Assessment for Cancer

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

Are you at risk of Hereditary Cancer? Your Guide to the Answers

Genetic testing for hereditary cancer

Versus. Cancer genomics Competitive Analysis

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

A guide to genetic testing for hereditary cancers

DNA Genetic Cancer Risk Test. Test Report

Genetic Risk Assessment for Cancer

Royal Marsden Breast Unit. BRCA testing learning resources pack (MCG LRP1)

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.

OvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Why Test for Hereditary Cancer in Preventive Care?

MOLECULAR SERVICES. mlabs.umich.edu

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor

Hereditary Cancer. Genetic Testing Services. The GeneDx Experience

Manchester Cytology Centre Synovial Fluid Analysis Service User Manual 2017/2018

Germline Testing for Hereditary Cancer with Multigene Panel

Myriad Financial Assistance Program (MFAP)

OncoGeneDx Test Requisition Form

Genetic testing and pancreatic disease

MSI positive MSI negative

OncoGeneDx Test Requisition Form

The Role of genetic Testing for Inherited Prostate Cancer Risk

Corporate Medical Policy

Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian

Use of panel tests in place of single gene tests in the cancer genetics clinic

Scottish E. coli O157/Shiga toxin-producing E. coli Reference Laboratory

BRCAplus. genetic testing for hereditary breast cancer

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

Understanding Your Positive Result. A guide to understanding your risk and taking action

patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention

Hereditary Cancer Products

Populations Interventions Comparators Outcomes Individuals: With a personal and/or family history suggesting an inherited cancer syndrome

A pathogenic mutation was identified in the BRCA1 gene.

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6

Clinical Cancer Genetics

Proactive Patient Paves the Way for Genetic Testing of Eight Family Members

Supplementary Information

PROVIDER POLICIES & PROCEDURES

Scottish Bacterial Sexually Transmitted Infections Reference Laboratory (SBSTIRL) User Manual Jan 2018

Manchester Cytology Centre Synovial Fluid Analysis Service User Manual 2016

Medical Policy Update

Mainstreaming Cancer Genetics (MCG) Information Pack

TumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention

Enabling Personalized

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

Genetic Testing for BRCA1 and BRCA2 Genes

CASE STUDY. Mutation-Specific Testing: Eligibility for PARP Inhibitor Therapy Established. Introduction. Patient Profile.

CASE STUDY. Germline Cancer Testing in A Proband: Extension of Benefits to Unaffected Family Members. Introduction. Patient Profile.

A CANCER GENETICIST S (2 ND ) BEST FRIEND IS THEIR PATHOLOGIST. Dr Alan Donaldson Consultant in Clinical Genetics St Michaels Hospital Bristol

Genetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017

Parkinson s Specialist Practitioner

Plasma-Seq conducted with blood from male individuals without cancer.

Informed Consent Columbia Whole Genome or Whole Exome Sequencing

patient guide PancNext genetic testing for hereditary pancreatic c a ncer Because knowing your risk can mean early detection and prevention

NGS for Cancer Predisposition

Genetic Testing for BRCA1 and BRCA2 Genes

Diagnostic and Treatment of Patients with Primary and Metastatic Breast Cancer

Genetic causes 90% Other causes 10% No variants are found in known genes associated with ADPKD

BowelGene. How do I know if I am at risk? Families with hereditary bowel cancer generally show one or more of the following clues:

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool

GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Genetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP

NEWSLETTER. Summer Test All Baby Boomers for Hepatitis C, Experts Say

Genetics & Precision Medicine Cancer Care

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

The Center for PERSONALIZED DIAGNOSTICS

Multigene Panel Testing for Hereditary Cancer Risk

Hereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com

Monitoring the Health of Transplanted Organs DONOR GENOTYPING MANUAL

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

patient guide ProstateNext genetic testing for hereditary prostate cancer Because knowing your risk can mean early detection and prevention

Hereditary Cancer Update: What do GPOs need to know?

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing. Policy Specific Section: September 27, 2013 January 30, 2015

COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014

ProstateGene What is hereditary prostate cancer? What are genes?

NeoTYPE Cancer Profiles

Information for You and Your Family

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Transcription:

TGL clinical User Guide The Institute of Cancer Research Brookes Lawley Building 15 Cotswold Road Sutton, Surrey SM2 5NG Page 1 of 7

TGL clinical This document describes the services provided by TGL clinical to internal and external users. The laboratory is situated in the Brookes Lawley Building, on the Sutton campus of the Institute of Cancer Research (ICR). TGL clinical provide a molecular diagnostic service for germline mutation analysis of genes that confer a predisposition to cancer. Uniquely TGL clinical provides an integrated laboratory and clinical interpretation service utilising expertise based at ICR and RMH to test for and interpret germline variation in cancer predisposition genes to aid and inform clinical management decisions. Staff list: Laboratory Director and Consultant Clinical Geneticist: Consultant Oncogeneticists: Clinical and Research Scientists: Scientific Officer: Database Manager: Statistician / Bioinformaticians: Operational Manager: Professor Nazneen Rahman Dr. Angela George Dr. Zoe Kemp Sheila Seal Dr. Shazia Mahamdallie Anthony Renwick Silvana Powell Emma Ramsay Bertha Adjei Anna Elliott Dr. Elise Ruark Dr. Shawn Yost Ann Strydom Page 2 of 7

Contact details: Laboratory contact: email: tgl@icr.ac.uk Postal address: Phone: 02087224122 TGLclinical laboratory Brookes Lawley Building The Institute of Cancer Research 15 Cotswold Road Sutton, Surrey SM2 5NG Website www.tglclinical.com Hours of service: 9.00am to 5.00pm, Monday to Friday (excluding bank holidays). Out of hour s service: No out of hours service is provided. Samples received after 5.00pm will be processed the following working day. Instructions for completion of the request form: Please fill ALL the fields provided with the relevant demographic/clinical information. For patient details, stickers with the patient s information can be used. Similarly, stickers can be used for the Consultant and referring hospital information. If some information is unknown or not applicable please fill the field in with UNKNOWN and N/A, respectively, rather that leaving it blank. Samples with attached request forms that do not contain all the relevant information can be rejected by the lab or put on hold until a new and completely filled request form has been received. Clinical details, required investigations and family history should be filled in where possible. If in doubt please contact us on the laboratory email or numbers given above. Consent: Upon receipt of samples, the laboratory assumes that appropriate consent has been obtained by the referring clinician. Page 3 of 7

Laboratory repertoire Test Genes included Cost A Cost B Turn-around time Panel tests Effective 1 st April 2017 BRCA panel BRCA1, BRCA2 355 675 90% < 3 weeks Breast / Ovarian panel BRCA1, BRCA2, TP53, PALB2, PTEN, MLH1, MSH2, MSH6, STK11, 430 817 90% < 4 weeks BRIP1, RAD51C, RAD51D, ATM, CHEK2 Lynch panel MLH1, MSH2, MSH6, PMS2, EPCAM 430 817 90% < 4 weeks Polyposis panel APC, MUTYH 430 817 90% < 4 weeks Renal panel BAP1, FH, FLCN, MET, PTEN, SDHB, VHL 430 817 90% < 4 weeks Pheo / Para panel SDHB, SDHC, SDHD, SDHAF2, MAX, TMEM127, NF1, RET, VHL 430 817 90% < 4 weeks Melanoma panel CDKN2A, CDK4 430 817 90% < 4 weeks Single gene tests Available for any gene included in a panel or one of the following genes: BUB1B, CDC73, CDH1, DICER1, MEN1, NF2, SMARCB1, SUFU, WT1 355 675 90% < 3 weeks Specific mutation (predictive) tests Available for any gene listed above in a panel test or single test 132 198 90% < 2 weeks The full coding sequence and intron-exon boundaries are analysed for small variants and exon deletions and duplications, except PMS2 (exons 1-11 only), EPCAM (exon 9 CNV only) POLE, POLD1 (select mutations only). For further details see www.tglclinical.com Cost A: UK NHS, UK self-funding, Middle and Low income countries (World bank classification) Cost B: Privately insured / funded, High income countries (World bank classification) https://datahelpdesk.worldbank.org/knowledgebase/arti cles/906519-world-bank-country-and-lending-groups Page 4 of 7

Cancer predisposition gene tests not performed by TGL clinical : When requests are received for cancer predisposition gene tests not offered by TGL clinical we will arrange testing by external providers. These providers will be selected based on their accreditation and known expertise for specific tests. When the results are received by TGL clinical, they are forwarded to the referring clinician with a clear indication as to the accreditation status of the external laboratory. Reporting times and accreditation status of the external labs are monitored by TGL clinical. DNA storage: We can store DNA from individuals for which no test is currently indicated, but for which it is considered possible that testing may be appropriate in the future. We do not store blood samples and thus if blood samples are received for storage the DNA is extracted and stored. Turnaround time standards TGL clinical strives to achieve the turnaround times outlined in the Laboratory repertoire table above which are all within the UK national target standards. Reporting of service and standards Where TGL clinical undertakes more than 10 tests per month for any individual institution a monthly report will be provided within the first seven working days of the following month, which will include information on the number of tests, the test type, the referring department and/or clinician, and the average turnaround times per test type Specimens required: Please send 2 x 9 ml of blood in PLASTIC EDTA tubes. Smaller volumes, for example from children, can be extracted if necessary, but we require a minimum of 2 ml. Samples should be sent on the day of collection and at ambient temperature. DNA samples can also be received. We strongly prefer to receive blood samples but if this is not possible, please contact the lab to discuss sending a saliva sample. Unsuitable samples: Clotted samples are occasionally unsuitable for molecular analysis, where possible the referring clinician will be informed and a new sample requested. Samples should be labelled with the patient first name and surname, D.O.B., hospital number and the date and time the sample was taken. The details on the sample tube must correspond to those on the request form. At least two unique identifiers are required. Page 5 of 7

Unidentifiable/Unlabelled/Broken samples will NOT be accepted. Where possible the referring clinician will be informed and a new sample requested. High risk blood samples (HIV, Hep B or C) received by TGL clinical must be indicated as such both on the blood tubes and the request form. These samples cannot be extracted by TGL clinical and so will be sent to an external provider for testing. This may in-turn affect the turnaround time for that specific sample. Please note that all DNA samples are stored indefinitely unless otherwise requested. Transportation of samples: At Royal Marsden Hospital, samples will be sent together with the request form from the phlebotomy unit to the Royal Marsden Hospital Central Pathology Department at the Sutton site, or can be delivered to TGL clinical pigeon hole at BLB reception. Samples should be dispatched as soon as possible after taking the sample. In the case of samples sent from the Chelsea site, they will be transported in the pathology containers on the RMH inter-site coach, to be delivered to the RMH Central Pathology. Samples will be then collected from the RMH Central Pathology and the BLB pigeon hole by laboratory staff and transported to the lab contained inside an opaque sample transportation bag. See the HSE guidance on biological agents http://www.hse.gov.uk/biosafety/biologagents.pdf. Blood and DNA samples from external users should be sent by first class mail, please address specimens to the TGL clinical postal address given above. Any diagnostic sample sent to the laboratory should be sent in accordance with the UN3373 regulations and the P650 Packaging instruction (http://www.un3373.com/info/regulations). Failure to abide by these regulations will result in the rejection of that sample by TGL clinical. Data protection: TGL clinical ensures secure and safeguarded storage of patient information and compliance with the Data Protection Act. Charges for tests: TGL clinical will provide notice of any charge in advance of any service being undertaken. Receipt of a test request by TGL clinical will be considered an agreement of that charge. Any changes in charges will be notified 3 months in advance of the change being effected. Quality control: All TGL clinical laboratory examination procedures that generate patient results include appropriate quality control measures. The results of all quality control samples are evaluated for every patient sample by an authorised member of staff prior to the release of the relevant patient results. Page 6 of 7

If during an individual examination process a quality control result is deemed to have failed and to invalidate patient results, then these patient results are repeated and are not released without successful accompanying quality control results. Reporting of Results: Reports are produced electronically and can be provided in either electronic or paper format according to the user s requirements. Reports can be printed to produce paper copies when requested but are stored within TGL clinical and routinely dispatched as electronic copies. Clinical interpretations: TGL clinical examination reports contain a clear explanation of the result and its clinical implications for the patient and their relatives. To obtain further clinical advice, contact the lab directly by email to tgl@icr.ac.uk. Please note that TGL clinical does not offer any interpretation of results obtained from external providers. Queries and Complaints procedure: Any questions about test methodology, interpretation of the results or complaints should be notified by email to tgl@icr.ac.uk, phone 02087224122 or by post to: TGLclinical laboratory Brookes Lawley Building The Institute of Cancer Research 15 Cotswold Road Sutton, Surrey SM2 5NG Queries will be responded to as soon as possible. Complaints will be acknowledged as being received within two working days. Feedback will be provided within seven working days and will include a timeline and process for more detailed consideration of the complaint if necessary. Page 7 of 7